Literature DB >> 3631700

Enzyme-linked immunosorbent assay for detection of antibodies to Rift Valley fever virus in ovine and bovine sera.

J M Meegan, R J Yedloutschnig, B A Peleg, J Shy, C J Peters, J S Walker, R E Shope.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) was developed for the rapid detection of antibodies to Rift Valley fever virus (RVFV) in ovine and bovine sera. Conditions to reduce nonspecific reactions were optimized. The ELISA results correlated with those of a plaque-reduction neutralization test, revealing 100% specificity and 90.7% sensitivity. In sera from sheep and cattle inoculated against RVFV, the hemagglutination-inhibition test in combination with the ELISA provided a better indication of response to killed RVFV vaccine than did either test alone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3631700

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  16 in total

1.  Comparison of dissociation-enhanced lanthanide fluorescent immunoassays to enzyme-linked immunosorbent assays for detection of staphylococcal enterotoxin B, Yersinia pestis-specific F1 antigen, and Venezuelan equine encephalitis virus.

Authors:  D R Smith; C A Rossi; T M Kijek; E A Henchal; G V Ludwig
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

2.  Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.

Authors:  John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Jing Wu; Roberta Pugh; Pooja Kanani; L Garry Adams; Shinji Makino; C J Peters
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

3.  Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Authors:  Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2013-08-20       Impact factor: 2.133

4.  Evaluation of an Indirect Enzyme-Linked Immunosorbent Assay Based on Recombinant Baculovirus-Expressed Rift Valley Fever Virus Nucleoprotein as the Diagnostic Antigen.

Authors:  Bonto Faburay; William C Wilson; Arss Secka; Barbara Drolet; D Scott McVey; Juergen A Richt
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

5.  Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.

Authors:  C Schmaljohn; L Vanderzanden; M Bray; D Custer; B Meyer; D Li; C Rossi; D Fuller; J Fuller; J Haynes; J Huggins
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  The S segment of Punta Toro virus (Bunyaviridae, Phlebovirus) is a major determinant of lethality in the Syrian hamster and codes for a type I interferon antagonist.

Authors:  Lucy A Perrone; Krishna Narayanan; Melissa Worthy; C J Peters
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

7.  Circulation of Rift Valley Fever Virus Antibody in Cattle during Inter-Epizootic/Epidemic Periods in Selected Regions of Tanzania.

Authors:  Linda Peniel Salekwa; Philemon Nyangi Wambura; Mirende Kichuki Matiko; Douglas M Watts
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

8.  Anamnestic immune response to dengue and decreased severity of yellow Fever.

Authors:  Ricardo O Izurieta; Maurizio Macaluso; Douglas M Watts; Robert B Tesh; Bolivar Guerra; Ligia M Cruz; Sagar Galwankar; Sten H Vermund
Journal:  J Glob Infect Dis       Date:  2009-07

9.  Assessing yellow Fever risk in the ecuadorian Amazon.

Authors:  Ricardo O Izurieta; Maurizio Macaluso; Douglas M Watts; Robert B Tesh; Bolivar Guerra; Ligia M Cruz; Sagar Galwankar; Sten H Vermund
Journal:  J Glob Infect Dis       Date:  2009-01

10.  Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep.

Authors:  John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Roberta Pugh; Elena Sbrana; William J Weise; L Garry Adams; Shinji Makino; C J Peters
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.